Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

摘要: Avibactam, a novel β-lactamase inhibitor, has recently been co-formulated with ceftazidime and approved for use in patients complicated intra-abdominal urinary tract infections, where no better treatment alternative exists. The basis its FDA approval the extensive clinical experience demonstration vitro animal models that addition of avibactam reverses resistance to extended-spectrum some carbapenemase-producing Enterobacteriaceae. Early data are promising, efficacy demonstrated infections. This review will summarize vitro, available on this agent date.